摘要
目的本研究旨在探讨格列美脲治疗2型糖尿病降糖的疗效,并对其安全性进行评价。方法选择我院2008年1月～2010年2月收治的100例2型糖尿病患者作为研究对象,随机分为观察组和对照组各50例,观察组给予格列美脲治疗,对照组采用格列本脲治疗,疗程3个月,观察比较两组治疗前后空腹血糖(FBG)、餐后2h血糖(2hPPG)、BIM、血脂、血压的变化以及不良反应情况。结果治疗组50例采用格列美脲治疗的总有效率为94.0%(47/50),明显高于对照组有效率70.0%,两组总有效率比较差异有统计学意义(P<0.05)。两组治疗3个月后,FBG、2hPBG、BMI均明显降低(P<0.05),且治疗组下降更明显,但两组间治疗前后分别比较,差异无统计学意义(P>0.05)。两组经3个月治疗后,两组的血脂TC、TG、HDL-C、LDL-C指标及血压指标SBP、DBP均变化不明显,两组组内及组间比较,差异均无统计学意义(P>0.05)。治疗组共计出现低血糖、头痛、腹痛、腹部不适2例,经对症处理后明显好转,不良反应的发生率为4.0%(2/50),对照组出现头晕、胃部不适等共8例,不良反应的发生率为16.0%(8/50),经对症治疗后均缓解或消失。两组不良反应发生率比较,差异有统计学意义(P<0.05)。结论格列美脲治疗2型糖尿病疗效较好,不良反应发生率较低,且可明显降低FBG、2hPBG,是一种值得临床推荐的安全、有效、理想的降糖药物。
Objective To explore the hypoglycemic effect of glimepiride on type 2 diabetes and its security evaluation. Methods We divided 100 cases of type 2 diabetes in our hospital from Jan. 2008 to Feb.2010 randomly divided into two groups： observation group and control group, each having 50 cases, and the observation group was given glimepiride for 3 months and the control group received glibenclamide for the same time. The fasting blood glucose （FBG）, postprandial 2h plasma glucose （2hPPG）, B/M, blood lipids, blood pressure change and adverse reactions were compared between the two groups before and after treatment. Results The total effective rate of the observation group was 94.0% （47/50）, much higher than that （70.0%） of the control group, with a significant difference between the two groups （P〈0.05）. FBG, 2hPBG and BMI were significantly lowered in both groups after 3- month treatment （P〈0.05） and the treatment group showed a more significantly decrease, with no significant difference between the two groups before and after treatment （P〉0.05）. There were no significant changes in lipids TC, TG, HDL-C and LDL-C and blood pressure SBP and DBP in both either group and between the two groups after 3-month treatment, showing no significant difference （P〉0.05）. Two cases showed hypo- glycemia, headache, abdominal pain and abdominal discomfort in the observation group which markedly improved after symptomatic treatment, the incidence of adverse reactions being 4.0% （2/50）. Eight cases showed dizziness and of stomach discomfort in the control group, which were relieved after treatment, the incidence of adverse reactions being 16.0% （8/50）. There was a significant difference in the incidence of adverse reactions between the two groups by Chi-square test （P〈0.05）. Conclusion Glimepiride has a better treat- ment effect on type 2 diabetes, with a lower incidence of adverse reactions, and it can significantly reduce the FBG and 2hPBG and is safe and effective, ideal hypoglycemic drug, worth a clinical recommendation
出处
《中国现代医生》
2010年第19期3-5,共3页
China Modern Doctor
关键词
格列美脲
2型糖尿病
不良反应
Glimepiride
2 diabetes mellitus
Adverse reactions
